Amid surging enthusiasm for antibody-drug conjugates (ADCs) in China, Shanghai Henlius Biotech Co. Ltd., a biologics arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is taking an adventurous yet patient approach to the feverish local R&D in the field.
Key Takeaways
-
Henlius has taken its first decisive moves in the pursuit of ADC candidates possessing novel linker-payloads, with its EGFR-targeting HLX42 and PD-L1-targeting HLX43 cleared for trials in Chinese patients in October.
On one hand, some risk-averse Chinese ADC players have adopted a fast-follower approach to design linker-payload platforms, a key component...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

